At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Randomized Phase III Trial of Lenalidomide Versus Observation Alone in Patients With Asymptomatic High-Risk Smoldering Multiple Myeloma
In Brief
A Phase 3 clinical trial evaluating Clinical Observation, Lenalidomide, and 1 other intervention for Light Chain Deposition Disease and Smoldering Multiple Myeloma. Active but no longer recruiting, targeting 226 participants across 607 sites in 3 countries.
Detailed Summary
This randomized phase II/III trial studies how well lenalidomide works and compares it to observation in treating patients with asymptomatic high-risk asymptomatic (smoldering) multiple myeloma. Biological therapies such as lenalidomide, may stimulate the immune system in different ways and stop cancer cells from growing. Sometimes the cancer may not need treatment until it progresses. In this case, observation may be sufficient. It is not yet known whether lenalidomide is effective in treating patients with high-risk smoldering multiple myeloma than observation alone.
Study Details
Timeline
Interventions
Undergo observation
Given PO
Ancillary studies